ConductScience.org, home

Paper19337019

The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients.

Duran C and 8 others. J Endocrinol Invest, 2009. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients. Papers, record 19337019. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19337019

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients.
PubMed
Journal
J Endocrinol Invest
PubMed
Year
2009
PubMed
Publication types
Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
0.32
iCite
Revised in PubMed
2026-01-28
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Duran CC
2Tuncel EE
3Ersoy CC
4Ercan II
5Selimoglu HH
6Kiyici SS
7Guclu MM
8Erturk EE
9Imamoglu SS

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AcarboseMajor topic
Blood GlucoseMajor topic
CarbamatesMajor topic
Diabetes Mellitus, Type 2Major topic
Hypoglycemic AgentsMajor topic
InsulinMajor topic
PiperidinesMajor topic
Drug Therapy, Combination
Female
Glycated Hemoglobin
Humans
Hypoglycemia
Insulin Glargine
Insulin, Long-Acting
Male
Middle Aged
Obesity
Weight Gain

Source PubMed

Download CSV of topics

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
19839094Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.Diabetes Care1998https://conductscience.org/library/papers/9839094PubMed
211315821Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.Diabetes Care2001https://conductscience.org/library/papers/11315821PubMed
37733122Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.Am J Med1995https://conductscience.org/library/papers/7733122PubMed
411221809Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus.Diabetes Obes Metab1999https://conductscience.org/library/papers/11221809PubMed
52951066A practical guide to basal and prandial insulin therapy.Diabet Med1985https://conductscience.org/library/papers/2951066PubMed
611574456Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes.Diabetes Care2001https://conductscience.org/library/papers/11574456PubMed
711815505Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).Diabetes Care2002https://conductscience.org/library/papers/11815505PubMed
87510610Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus.Drugs1993https://conductscience.org/library/papers/7510610PubMed
97734015The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.Ann Intern Med1994https://conductscience.org/library/papers/7734015PubMed
1012860485Insulin glargine: a systematic review of a long-acting insulin analogue.Clin Ther2003https://conductscience.org/library/papers/12860485PubMed
117587856Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure.Diabetes Care1995https://conductscience.org/library/papers/7587856PubMed
1211315844Combination therapies with insulin in type 2 diabetes.Diabetes Care2001https://conductscience.org/library/papers/11315844PubMed
131406860Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus.N Engl J Med1992https://conductscience.org/library/papers/1406860PubMed
1411323089Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study.Diabetes Res Clin Pract2001https://conductscience.org/library/papers/11323089PubMed
1512823235Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients.Diabet Med2003https://conductscience.org/library/papers/12823235PubMed
1615618112Standards of medical care in diabetes.Diabetes Care2005https://conductscience.org/library/papers/15618112PubMed
1710466661
Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe.
Lancet1999https://conductscience.org/library/papers/10466661PubMed
188572835Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.Arch Intern Med1996https://conductscience.org/library/papers/8572835PubMed
1915334790Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.Diabetes Nutr Metab2004https://conductscience.org/library/papers/15334790PubMed
2015647580Insulin analogues.N Engl J Med2005https://conductscience.org/library/papers/15647580PubMed

See all 29 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
32621047A time to revisit the two oldest prandial anti-diabetes agents: acarbose and repaglinide.Endocrine2020https://conductscience.org/library/papers/32621047PubMed
24236131Comparisons of the efficacy of alpha glucosidase inhibitors on type 2 diabetes patients between Asian and Caucasian.PLoS One2013https://conductscience.org/library/papers/24236131PubMed
22571453Secreted factors from adipose tissue increase adipogenic differentiation of mesenchymal stem cells.Cell Prolif2012https://conductscience.org/library/papers/22571453PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19337019

GET https://conductscience.org/api/papers/v1/19337019/references?page=2